Arcturus Therapeutics Holdings Inc.

NasdaqGM ARCT

Arcturus Therapeutics Holdings Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2024

Arcturus Therapeutics Holdings Inc. Return on Capital Employed (ROCE) is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Arcturus Therapeutics Holdings Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2023 was 19.49%, a 133.65% change year over year.
Arcturus Therapeutics Holdings Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2022 was -57.93%, a -14.86% change year over year.
Arcturus Therapeutics Holdings Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2021 was -50.44%, a -32.03% change year over year.
Arcturus Therapeutics Holdings Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2020 was -38.20%, a -12.19% change year over year.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

NasdaqGM: ARCT

Arcturus Therapeutics Holdings Inc.

CEO	Mr. Joseph E. Payne M.Sc.
IPO Date	May 22, 2013
Location	United States
Headquarters	10628 Science Center Drive
Employees	180
Sector	Healthcare
Industries Vaccines Biotechnology Pharmaceuticals

Description

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.

Key trends

Past 5 years